Advertisement
Document › Details
Novimmune S.A.. (1/4/17). "Press Release: Novimmune Grants Tiziana an Exclusive License to NI-1201, an anti-IL-6R Monoclonal Antibody for the Treatment of Autoimmune and Inflammatory Diseases". Geneva.
Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, and Tiziana Life Sciences (TILS), have signed a second collaboration agreement granting Tiziana exclusive rights to develop and commercialize its anti-IL-6R monoclonal antibody, NI-1201.
Anti-IL6R antibodies are marketed or in development for a range of inflammatory conditions including rheumatoid arthritis. Tiziana intends to explore the development of NI-1201 in Non-alcoholic Steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases, as well as foralumab (NI-0401), the first antibody that Novimmune licensed to Tiziana in December 2014. Financial details were not disclosed.
“Two years ago, we entered into our first collaboration with Tiziana and we have been very pleased with the progress they have made with NI-0401, currently in phase 2 clinical development. We are delighted to have signed this second agreement to move NI-1201 forward, and we believe this is a very exciting molecule which complements Tiziana’s portfolio.” said Novimmune Chairman and Chief Executive Officer, Eduard Holdener.
About Novimmune
Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and currently employs 122 people. More information is available on the company website at www.novimmune.com.
Contact:
Adrian Mills
+41 (0) 61 201 13 27
amills@novimmune.com
Record changed: 2023-06-05 |
Advertisement
More documents for Novimmune S.A.
- [1] Novimmune S.A.. (6/20/18). "Press Release: TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody". New York, NY & Geneva....
- [2] Nordic Nanovector ASA. (6/1/18). "Press Release: Nordic Nanovector Strengthens Management Team with Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy". Oslo....
- [3] Novimmune S.A.. (7/18/17). "Press Release: Novimmune and Shire Sign License Agreement Deepening Bispecific Antibody Research Collaboration". Geneva....
- [4] Novimmune S.A.. (3/27/17). "Press Release: Novimmune Opens a Branch Office in Basel". Geneva & Basel....
- [5] Novimmune S.A.. (2/13/17). "Press Release: Novimmune and LegoChem Biosciences Enter Research Collaboration on Antibody Drug Conjugate". Geneva....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top